• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sustained Release Injectables to 2020 - Product Image

Sustained Release Injectables to 2020

  • Published: January 2014
  • Greystone Associates

Formulations, Dosing, Devices, Markets and Forecasts

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, READ MORE >

Executive Summary

Injectable Drug Market Dynamics

The Trend toward Self-Administration
Shifting Demographics
Injectable Drug Formulation Technology
Innovation in Injectable Device Designs
Therapeutic Demand Drivers
Competitive Landscape
Risk Factors

Sustained Release Injectables - Branded Formulation Technologies

Biodegradable Polymers
PEG
PLG/PLA/PLGA
Polyether ester
Branded SR Formulation Technologies
ChroniJect
CriticalMix
Depofoam
LinkeRx
Liposomes
Medisorb
Medusa
Optisomes
OxtoDEX
SABER/SAIB
SynBiosys
Supercritical Fluid

Approved Sustained Release Injectables by Therapeutic Indication

Acromegaly
lanreotide acetate
octreotide acetate
Hormone Therapy
Medroxyprogesterone
Somatropin
Infectious Disease
Interferon
Metabolic
Exenatide
Oncology
Neoplastic Meningitis
Cytarabine
Prostate
leuprolide acetate
leuprolide acetate
triptorelin pamoate
Schizophrenia
Fluphenazine
Haloperidol
paliperidone palmitate
olanzapine
risperidone
Substance Abuse
naltrexone
Reproductive Health
Estradiol valerate
Depo-estradiol
Depo-testosterone

Development-Stage SR Injectable Drug Candidate Assessment

Addiction
Antivirals
Hormones
Immune Modulators
Incretin Mimetics
Local Anesthetics
Opioid Antagonists
Psychotropics
Antineoplastics

SR Injectables – Therapeutic Sector Impact Analysis & Forecasts

Addiction
Autoimmune Diseases
Diabetes
Infectious Disease
Macular Degeneration
Metabolic Diseases
Neurology
Oncology
Pain Management
Reproductive Health

Sustained Release Injectables – Company Profiles

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos